In conclusion, our study demonstrates that low-dose decitabine induces degradation of IκBα by β-TrCP through a proteasome degradation pathway, to boost NF-κB activation and thus promotes the proliferation of IFN-γ+CD4+ T cells and enhances the anti-tumor immune activity of CD4+ T cells (Figure 6F). The gene discussed is BTRC; the disease is neoplasm.